The induction of these regulatory pathways represents a major obstacle in developing TLR agonists as cancer immunotherapeutics, and the promise of using TLR agonists to eradicate tumor cells probably won’t be realized unless we block the negative regulators (IL-10, Treg, and PD-L1, etc) and tip the balance toward an overwhelming pro-inflammatory response. The gene discussed is IL10; the disease is cancer.